INIVATA
Inivata is a clinical cancer genomics company harnessing the emerging potential of circulating DNA analysis to improve testing and treatment for oncologists and their patients. Unlike conventional invasive biopsies, Inivata detects and analyses genomic material from a cancer patient’s cell-free, circulating tumor DNA (ctDNA) which can be collected through a simple blood sample. This non-invasive approach – a liquid biopsy – offers a revolution in how cancer is detected, monitored, and treated.
INIVATA
Industry:
Biotechnology Genetics Health Care Medical Device
Founded:
2014-01-01
Address:
Cambridge, Massachusetts, United States
Country:
United States
Website Url:
http://www.inivata.com
Total Employee:
51+
Status:
Active
Contact:
(440) 207-6389
Email Addresses:
[email protected]
Total Funding:
164.35 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SSL By Default LetsEncrypt Nginx Amazon Person Schema GStatic Google Static Content Gravatar Profiles Apple Mobile Web App Capable
Similar Organizations
BioIntelliSense
BioIntelliSense, a continuous health monitoring and clinical intelligence company with medical-grade wearable devices and Data-as-a-Service.
Color
Color is a complete platform for healthcare delivery.
Helix
Helix is a population genomics company that is working to advance genomics research and integrate genomic data into clinical care.
Human Longevity
Human Longevity is a genomic-based, health intelligence company empowering proactive healthcare and enabling a life better lived.
NeoGenomics
NeoGenomics is a cancer reference laboratory that provides cancer testing and partnership programs to pathologists and oncologists.
Ribon Therapeutics
Ribon Therapeutics is a biotechnology company focused on the development of therapeutics treatments targeting stress support pathways.
Senseonics
Senseonics is a medical device startup company that focuses on the design, development, and commercialization of glucose monitoring systems.
Voyager Therapeutics
Voyager Therapeutics is a biotechnology company specializing in gene therapy and neurology.
Current Advisors List
Current Employees Featured
Founder
Investors List
Janus Henderson Investors
Janus Henderson Investors investment in Series C - Inivata
Soleus Capital
Soleus Capital investment in Series C - Inivata
Farallon Capital Management
Farallon Capital Management investment in Series C - Inivata
NeoGenomics
NeoGenomics investment in Corporate Round - Inivata
Johnson & Johnson Innovation
Johnson & Johnson Innovation investment in Series B - Inivata
Cambridge Innovation Capital
Cambridge Innovation Capital investment in Series B - Inivata
IP Group
IP Group investment in Series B - Inivata
RT Ventures
RT Ventures investment in Series B - Inivata
Woodford Investment Management
Woodford Investment Management investment in Series B - Inivata
Future Planet Capital
Future Planet Capital investment in Series B - Inivata
Key Employee Changes
| Date | New article |
|---|---|
| 2021-12-13 | Inivata Appoints David Eberhard MD, PhD as Chief Medical Officer |
Official Site Inspections
http://www.inivata.com Semrush global rank: 4.7 M Semrush visits lastest month: 2.04 K
- Host name: 23.185.0.2
- IP address: 23.185.0.2
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Inivata"
Inivata - Crunchbase Company Profile & Funding
Inivata may be growing as evidenced by its acquisition by oncology testing company NeoGenomics for $390 million, which is a significant financial transaction indicating expansion. Additionally, the company is listed among …See details»
NeoGenomics to Acquire Inivata - Combining Best-In …
MYERS, FL / ACCESSWIRE / May 5, 2021 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, announced today that it has …See details»
NeoGenomics Completes Inivata Acquisition
Inivata Chief Executive Officer, Dr. Clive Morris, will become the President of Inivata and will report to Mark Mallon. About NeoGenomics, Inc. NeoGenomics, Inc. specializes in cancer genetics testing and information services, providing …See details»
Inivata to be Acquired by NeoGenomics - One Nucleus
Research Triangle Park, NC, USA and Cambridge, UK, 5 May 2021 -- Inivata, a leader in liquid biopsy, today announces that NeoGenomics, Inc (NASDAQ: NEO.), a leading provider of …See details»
Inivata to be Acquired by NeoGenomics - Yahoo Finance
May 5, 2021 Inivata to be Acquired by NeoGenomics Exercise of purchase option to acquire remaining Inivata equity interest for $390m Inivata to become a liquid biopsy focused division of NeoGenomics Research ...See details»
Inivata Company Profile 2024: Valuation, Investors, …
Inivata General Information Description. Developer of medical tests designed to detect cancer using liquid biopsies. The company's platform focuses on harnessing the potential of circulating tumor DNA (ctDNA) analysis, monitoring …See details»
NeoGenomics Completes Inivata Acquisition - Combining Best-In …
Jun 18, 2021 Acquisition establishes NeoGenomics as a technology leader in the minimal residual disease (MRD) testing market; FT. MYERS, FL / ACCESSWIRE / June 18, 2021 / …See details»
NeoGenomics and Liquid Biopsy Subsidiary Inivata and …
Sep 7, 2022 Inivata's technology is based on pioneering research from the Cancer Research UK Cambridge Institute, University of Cambridge. About the RaDaR TM assay Inivata's RaDaR™ …See details»
NeoGenomics to acquire Inivata for $390M after success of lung …
May 6, 2021 Inivata CEO Clive Morris will become president of the division, reporting directly to NeoGenomics CEO Mark Mallon. RELATED: NeoGenomics to acquire Genoptix in near …See details»
Cancer Research UK’s spinout Inivata to be acquired by …
May 5, 2021 Inivata to become a liquid biopsy focused division of NeoGenomics; Research Triangle Park, NC, USA and Cambridge, UK, 5 May 2021-- Inivata, a leader in liquid biopsy, …See details»
Inivata - LinkedIn
Inivata | 5,966 followers on LinkedIn. A leader in liquid biopsy transforming the lives of cancer patients and their families. | Inivata is a leader in liquid biopsy. Its InVision® platform unlocks …See details»
Inivata to be Acquired by NeoGenomics - GlobeNewswire
May 5, 2021 Research Triangle Park, NC, USA and Cambridge, UK, 5 May 2021 -- Inivata, a leader in liquid biopsy, today announces that NeoGenomics, Inc (NASDAQ: NEO.), a leading …See details»
Inivata - Funding, Financials, Valuation & Investors - Crunchbase
How much funding has this organization raised over time? Show . Announced Date . Transaction Name . Number of Investors . Money Raised . Lead Investors . Access exclusive financial …See details»
Inivata Company Profile - Office Locations, Competitors ... - Craft
Inivata has 5 employees across 3 locations, $129.4 m in total funding, and £128.19 k in annual revenue in FY 2018. See insights on Inivata including office locations, competitors, revenue, …See details»
Inivata notes completion of acquisition by NeoGenomics
Research Triangle Park, NC, USA and Cambridge, UK, 18 June 2021 — Inivata, a leader in liquid biopsy, today announces that NeoGenomics, Inc (NASDAQ: NEO.) has completed its …See details»
NeoGenomics' Liquid Biopsy Subsidiary Inivata Announces Clinical ...
Oct 19, 2021 MYERS, FL / ACCESSWIRE / October 19, 2021 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services and global …See details»
Inivata - Contacts, Employees, Board Members, Advisors & Alumni
Organization. Inivata . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. Highlights. Employee Profiles 8. Number of Board …See details»
Inivata to be Acquired by NeoGenomics - BioSpace
May 5, 2021 About Inivata Inivata is a leader in liquid biopsy. Its InVision® platform unlocks essential genomic information from a simple blood draw to guide and personalize cancer …See details»
PRESS RELEASE: Inivata And The European Organisation For …
Oct 29, 2019 Inivata to provide ctDNA liquid biopsy using its InVisionFirst®-Lung test to analyze resistance in patients treated with lorlatinib. Study is being funded by Pfizer. Research …See details»
FDA Grants Breakthrough Device Designation for Inivata’s RaDaR™ …
Mar 9, 2021 For more information, please go to www.inivata.com. Follow Inivata on Twitter @Inivata. Media Contacts: Consilium Strategic Communications Chris Gardner/Angela …See details»